You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

Litigation Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

✉ Email this page to a colleague

« Back to Dashboard

Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Docket	⤷ Sign Up	Date Filed	2017-08-16
Court	District Court, D. Delaware	Date Terminated	2020-07-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,010,533; 10,052,385; 8,609,707; 8,791,270; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Small Molecule Drugs cited in Cephalon, Inc. v. Slayback Pharma Limited Liability Company

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-19	164	Status Report	Book patents have issued during the course of the current litigation. U.S. Patent No. 10,010,533 (“the…infringes the ’707 patent, the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent by seeking …assignee of U.S. Patent Nos. 8,609,707 (the “’707 patent”), 9,265,831 (the “’831 patent”), 9,572,796 (the…9,034,908 (the “’908 patent”), 9,144,568 (the “’568 patent”), 9,572,887 (the “’887 patent”), 9,597,397 (the…(the “’397 patent”), 9,597,398 (the “’398 patent”), 9,597,399 (the “’399 patent”), 9,000,021 (the “’021	External link to document
2018-12-04	207		any of the three disputed claims of U.S. Patent No. 8,791,270 that were identified in the parties’ Joint…any of the three disputed claims of U.S. Patent No. 8,791,270 that were identified in the parties’ Joint…to the same issue regarding one or more of the patents-in- suit shall count as one interrogatory. To the… Joint Claim Construction Brief as to the ’270 Patent January 18, 2019 (If Necessary) Final Invalidity…2019 Claim Construction Hearing as to the °270 Patent February 5, 2019 (If Necessary) Opening Expert	External link to document
2019-09-05	315	Redacted Document	the “’831 patent”), 9,572,796 (the “’796 patent”), 9,572,797 (the “’797 patent”), 10,010,533 (the “’533…following patents: U.S. Patent Nos. 8,791,270 (the “’270 patent”), 8,609,707 (the “’707 patent”), 9,265,831…533 patent”), 9,034,908 (the “’908 patent”), 9,144,568 (the “’568 patent”), 9,572,887 (the “’887 patent…,397 (the “’397 patent”), 9,597,398 (the “’398 patent”), 9,597,399 (the “’399 patent”), 10,052,385 (the…(the “’385 patent”), 9,000,021 (the “’021 patent”), and 9,579,384 (the “’384 patent”). 2.	External link to document
2019-10-25	349	- Transcript	14 So this is U.S. Patent No. 9,265,831. 15 A. Okay. 16 Q.…x27;887 patent, 7 DTX-5 for the '568 patent and DTX-13 for the '399 patent, …Where are we on the '270 7 patent, the '270 patent as far as judgment? My …Objection. Mr. Feldman said patent. 6 This is not a patent. 7 … is a patent case. I 13 thought it would be finally nice to show someone a patent.	External link to document
2019-11-05	366	Redacted Document	expiration of U.S. Patent Nos. 8,609,707; 9,265,831; 9,572,796; 9,572,797; 10,010,533; 9,034,908; 9,144,568…minutes or less. PTX-312 (’568 patent); DTX-13 (’399 patent); DTX-9 (’887 patent). 137. The claims …less, with many (’568 patent claims 11, 18, ’399 patent claim 15, ’887 patent claim 13) claiming about…about 50 ml. PTX-312 (’568 patent); DTX-13 (’399 patent); DTX-9 (’887 patent). 138. Some claims…for ’568 patent claim 22 and July 10, 2012, for ’568 patent claims 11 and 18 and ’887 patent claim 13	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.